Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis

BACKGROUND: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Nucl Med Mol Imaging
Main Authors: Seifert, Robert, Kessel, Katharina, Schlack, Katrin, Weckesser, Matthias, Bögemann, Martin, Rahbar, Kambiz
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338828/
https://ncbi.nlm.nih.gov/pubmed/32062682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04703-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items